Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors-Reference-Cited by-同舟云学术

Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors

Published:2018-12 Issue:1 Volume:37 Page:
ISSN:1756-9966
Container-title:Journal of Experimental & Clinical Cancer Research
language:en
Short-container-title:J Exp Clin Cancer Res

Author:

Su Yanrong^ORCID,Hopfinger Nathan R.,Nguyen Theresa D.,Pogash Thomas J.,Santucci-Pereira Julia,Russo Jose

Funder

Pennsylvania Cancer Cure Grant

NIH Core Grant

Barbara and Joseph Breitman donation

the Flyers wives donation.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s13046-018-0988-8.pdf

Reference63 articles.

1. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer--current status and future directions. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2009;20(12):1913–27.

2. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279.

3. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533–40.

4. Andre F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 2012;23(Suppl 6):vi46–51.

5. Fallahpour S, Navaneelan T, De P, Borgo A. Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. CMAJ open. 2017;5(3):E734–e9.

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bifunctional HDAC and DNMT inhibitor induces viral mimicry activates the innate immune response in triple-negative breast cancer;European Journal of Pharmaceutical Sciences;2024-06

2. Kilo-Scale Synthesis of the Dinucleotide DNA Methyltransferase Inhibitor Guadecitabine;Organic Process Research & Development;2024-05-10

3. Quantitative Pattern of hPTMs by Mass Spectrometry-Based Proteomics with Implications for Triple-Negative Breast Cancer;Journal of Proteome Research;2024-03-05

4. Searching for Essential Genes and Targeted Drugs Common to Breast Cancer and Osteoarthritis;Combinatorial Chemistry & High Throughput Screening;2024-02

5. Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment;European Journal of Medicinal Chemistry;2024-01